查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2092502

皮膚鱗狀細胞癌（cSCC）：新型療法、未滿足的需求和TPP洞察報告，2026年

Cutaneous Squamous Cell Carcinoma (cSCC) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 53 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 德國 cSCC 市場預計將從 2025 年的 1.89 億美元成長到 2035 年的 3.57 億美元。
  • 以下因素正在推動市場成長：
  • 發病率和診斷率上升
  • 免疫查核點抑制劑在進行晚期疾病治療的應用
  • 未來的成長取決於早期診斷和免疫腫瘤療法的推廣。

皮膚鱗狀細胞癌 (cSCC) 的新療法及對 TPP 的深入理解

Thelansis 發布的《皮膚鱗狀細胞癌 (cSCC)：新型療法、未滿足的需求和 TPP 洞察報告，2026 年》全面分析了該適應症的關鍵新興療法和主要藥物發現機會，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、臨床試驗設計以及關鍵意見領袖 (KOL) 的見解。

皮膚鱗狀細胞癌（cSCC）概述

皮膚鱗狀細胞癌 (cSCC) 是一種常見的皮膚癌，如果早期發現，通常可以透過手術治愈，但相當一部分病例會發展為局部進展、復發或轉移。在這種階段，預後通常會迅速惡化，治療選擇也十分有限。 PD-1查核點免疫療法的出現大大改變了這一現狀。對於已無法進行手術治療的患者，該療法能夠提供持續的疾病控制，並迅速成為晚期疾病的標準治療方案。近年來，其作用機制已拓展至治療的早期階段，監管機構也開始支持在手術或放射治療後，對復發風險高的患者使用該療法。臨床研究也不斷拓展其應用範圍，包括術前腫瘤縮小。這項進展代表著 cSCC 治療領域更廣泛的變革。免疫療法不再是晚期癌症的最後手段，而是融入整個治療過程的工具，其目標不僅在於疾病擴散後獲得緩解，更在於預防復發。對於相關人員，cSCC 表明，單一的已證實機制可以貫穿所有疾病階段，並有可能重塑該疾病領域的護理標準。

主要亮點

  • 德國預計，到 2035 年，新增 cSCC 病例數將從 2025 年的 38,675 例增加到 44,883 例，這反映了人口老化和累積紫外線照射導致的疾病負擔日益加重。
  • cSCC 是第二常見的非黑色素瘤皮膚癌，在某些患者中，它會發展為局部晚期或轉移性疾病。
  • 發病率上升與預期壽命延長、免疫抑制和檢測率提高有關。
  • 免疫療法的廣泛應用正在改善進行性皮膚鱗狀細胞癌患者的治療效果。

透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：

  • 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
  • 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

  • PowerPoint簡報
  • MS Excel

主要問題

  • 詳細的競爭格局趨勢
  • 管道分析
  • 符合新興療法條件的患者
  • 大公司
  • 主要作用機制
  • 發布日期預測等。
  • 臨床試驗趨勢分析
  • 目標患者群
  • 試驗終點
  • 測試設計
  • 受試者招募標準等。
  • 未滿足的需求和機遇
  • 目前主要療法的有效性
  • 未滿足需求的關鍵領域
  • 主要未滿足需求的市場規模估算
  • 目標產品概況
  • 屬性和級別
  • 醫生開立的處方
  • 預期患者佔有率
  • 關鍵意見領袖對領先新興療法的見解
  • 意識
  • 預期用途/處理線
  • 以滿足重大未滿足需求的程度
  • KOL評論

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Replimune, Inc.
  • Incyte Corporation
  • Regeneron Pharmaceuticals
  • Merck Sharp &Dohme LLC
  • Philogen SpA
  • EvolveImmune United, Inc.
  • Rakuten Medical, Inc.
  • Hummingbird Bioscience
  • Ankyra Therapeutics, Inc.
  • Bicara Therapeutics
  • KaliVir Immunotherapeutics
  • Immunitas Therapeutics
  • Memgen, Inc.
  • Boundless Bio, Inc.
  • Medicenna Therapeutics, Inc.

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要療法概述及關鍵意見領袖見解
  • 新興療法
  • 重點
  • 診斷和治療過程/演算法
  • 領先的新興療法—概述和關鍵意見領袖見解

第3章 產品屬性分析

  • 重點
  • 科學屬性
  • 商業性屬性
  • 產品定位

第4章：初步調查

  • 目前治療狀態
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療環境
  • 當前挑戰
  • 未滿足的需求
  • 新興療法
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療前景
  • 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

  • 新興療法的主要未滿足需求和未來成就
  • TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

簡介目錄

Cutaneous Squamous Cell Carcinoma Emerging Therapy and TPP Insights

Thelansis's "Cutaneous Squamous Cell Carcinoma (cSCC) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Cutaneous Squamous Cell Carcinoma (cSCC) Overview

Cutaneous squamous cell carcinoma (cSCC) is a common skin cancer that is usually curable with surgery when caught early, but a meaningful subset of cases become locally advanced, recurrent, or metastatic, at which point outcomes historically worsened sharply and treatment options were limited. That calculus changed with the arrival of PD-1 checkpoint immunotherapy, which delivered durable disease control for patients whose cancer could no longer be managed surgically and quickly became the established standard for advanced disease. More recently, the same mechanism has moved earlier in the treatment journey, with regulators now supporting its use after surgery and radiation in patients considered high risk for recurrence, and clinical investigation extending further into shrinking tumors before surgery altogether. This progression signals a broader shift in cSCC: immunotherapy is no longer a last resort for advanced disease but a tool woven throughout the treatment continuum, aimed at preventing recurrence rather than only responding once disease has spread. For stakeholders, cSCC shows how one validated mechanism can expand across stages to reshape a category's standard of care.

Key Highlights

  • In Germany, incident cSCC cases are projected to increase from 38,675 in 2025 to 44,883 by 2035, reflecting a growing disease burden driven by aging populations and cumulative UV exposure.
  • cSCC is the second most common non-melanoma skin cancer, with a subset of patients progressing to locally advanced or metastatic disease.
  • Rising incidence is associated with increased life expectancy, immunosuppression, and improved detection rates.
  • Growing adoption of immunotherapy is improving outcomes in advanced cSCC patients.

Market Overview

  • The Germany cSCC market is projected to grow from $189M in 2025 to $357M by 2035.
  • Market growth is driven by:
  • Increasing incidence and diagnosis rates
  • Adoption of immune checkpoint inhibitors for advanced disease
  • Future growth will depend on earlier diagnosis and expansion of immuno-oncology therapies.

Insights driven by surveys with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs
  • Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
  • Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
  • Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
  • KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Replimune, Inc.
  • Incyte Corporation
  • Regeneron Pharmaceuticals
  • Merck Sharp & Dohme LLC
  • Philogen S.p.A.
  • EvolveImmune United, Inc.
  • Rakuten Medical, Inc.
  • Hummingbird Bioscience
  • Ankyra Therapeutics, Inc.
  • Bicara Therapeutics
  • KaliVir Immunotherapeutics
  • Immunitas Therapeutics
  • Memgen, Inc.
  • Boundless Bio, Inc.
  • Medicenna Therapeutics, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
  • Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)